October 10, 2012 — El Camino Hospital announced it is the first facility in the San Francisco Bay Area to adopt Volpara breast density measurement software from Matakina Intl. The hospital’s breast health center is among the latest California breast imaging facilities that have adopted the objective breast density assessment tool designed to improve early detection among women with dense breasts, including Sutter Health Foundation Women’s Center in Santa Rosa and North Valley Breast Clinic in Redding.

“It is critical for physicians and patients to have as many resources available as possible to detect breast cancer, especially among women for whom the traditional mammogram may not be enough,” said Imtiaz Qureshi, M.D., medical director and chief of radiology at El Camino Hospital in Mountain View. “Volpara, when used in concert with advanced imaging technology, can increase the chances for an accurate diagnosis leading to early treatment and a greater possibility for long-term survival.”

Cleared by the U.S. Food and Drug Administration (FDA), HealthCanada, Australia’s Therapeutic Goods Association (TGA) and CE-marked, Volpara is in use at sites across the globe, helping radiologists assess breast density more objectively and helping them better consider who might benefit from additional screening. Volpara automatically generates objective, automatic measurement of volumetric breast density values under the Volpara Density Grade (VDG) – a refined grading system which correlates with the American College of Radiology BIRADS Density Grading Classifications. Volpara is FDA-cleared for all digital mammography units, and integration with other digital mammography systems, CAD systems and mammography reporting system are also under way.

“El Camino Hospital is well known as an early adopter of innovative technology to help them deliver better care to their patients. Coming on the heels of California becoming the fifth state to enact density inform legislation, El Camino continues to demonstrate this leadership with the implementation of the Volpara breast imaging software which provides an accurate, objective breast density measurement designed to improve radiologists’ understanding of breast density and help them in guiding patients to make appropriate screening decisions,” said Ralph Highnam, CEO of Matakina Intnl.

For more information: www.elcaminohospital.org, www.matakina.com


Related Content

News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
News | Mammography

Nov. 26, 2024 — GE HealthCare has introduced the Pristina Via* mammography system designed to enhance the screening ...

Time December 02, 2024
arrow
News | Artificial Intelligence

Dec. 2, 2024 — Lunit recently unveiled follow-up findings from the ScreenTrustCAD trial. This study, conducted at Capio ...

Time December 02, 2024
arrow
Subscribe Now